Detection of Circulating Tumor Cells in Patients With Sarcomas

Leiomyosarcoma Clinical Trial

— CTCS  

Official title:

Detection of Circulating Tumor Cells in Patients With Metastatic Sarcomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02983539
• Other study ID #: ACFrance
• Status: Recruiting
• Start date: October 2015
• Est. completion date: June 2018

Study information

• Verified date: June 2018
• Source: AC Camargo Cancer Center
• Contact: Ludmilla Chinen, PhD
• Phone: 55 11 21895000
• Email: ludmilla.chinen[@]cipe.accamargo.org.br
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The sarcomas represent 1% of all cancers in adults, 8% in adolescents and young people, and 10% in children. Even though it is a rare cancer, it contributes to a significant loss of years of life in comparison with other types of cancer, due the fact that it affects children and young people. The diagnosis and treatment are difficult, considering the diversity and rarity of this disease. In addition, on average, more than 50% of patients with high-grade sarcoma present tumor relapse and distant recurrence is considered the main cause of death. The presence of Circulating Tumor Cells (CTCs) in the blood of patients with sarcoma may be an early marker of tumor invasion, because it is known that the CTCs circulate in the blood for months or years before the development of metastases. The CTCs can be used to monitor the response of the tumor to treatment, in order to match time, dose, and type of therapy.

Objectives: collect blood from patients with different types of sarcoma (leiomyosarcoma, synovial sarcoma, pleomorphic sarcoma and liposarcoma) in order to isolate and quantify CTCs. The investigators also have an intention to identify genes of resistance to treatment in these cells.

Description:

Methodology: This is a prospective study, to be made by whole blood collection from 40 patients with different types of sarcomas (leiomyosarcoma, pleomorphic sarcoma, synovial sarcoma and liposarcoma). The collections will be made in three different moments: before the beginning of the treatment, during and at the end of this (8 mL). Blood samples will be processed and filtered on ISET system for the isolation and quantification of CTCs. Later, it will be performed immunocytochemistry (ICQ) single and/or double staining for protein assessment. The following proteins will be assessed: CD45, MRP1, MRP2 and MRP7.

Expected Results: The investigators hope that this study can show if the CTCs can be used as "liquid biopsy" in patients with leiomyosarcoma, synovium and pleomorphic sarcoma and liposarcoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 18 years or more;

• types of sarcomas: leiomyosarcoma, pleomorphic sarcoma, synovial sarcoma and liposarcoma.

• extension of the disease determined by physical examination and imaging;

• measurable disease by RECIST criteria (Response Evaluation Criteria in Solid Tumors);

Exclusion Criteria:

• patients who have undergone previous therapy in the last three weeks;

• patients with a history of other cancer in the past two years.

Related Conditions & MeSH terms

• Leiomyosarcoma
• Liposarcoma
• Neoplastic Cells, Circulating
• Pleomorphic Liposarcoma
• Sarcoma
• Sarcoma, Synovial
• Synovial Sarcoma

Locations

Country	Name	City	State
Brazil	ACCamargo Cancer Center	Sao Paulo	SP

Sponsors (1)

Lead Sponsor	Collaborator
AC Camargo Cancer Center

Country where clinical trial is conducted

Brazil, 

References & Publications (2)

Abdallah EA, Fanelli MF, Souza E Silva V, Machado Netto MC, Gasparini Junior JL, Araújo DV, Ocea LM, Buim ME, Tariki MS, Alves Vda S, Piana de Andrade V, Dettino AL, Abdon Lopes de Mello C, Chinen LT. MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer. Int J Cancer. 2016 Aug 15;139(4):890-8. doi: 10.1002/ijc.30082. Epub 2016 Apr 28. — View Citation

Chinen LT, Mello CA, Abdallah EA, Ocea LM, Buim ME, Breve NM, Gasparini JL Junior, Fanelli MF, Paterlini-Bréchot P. Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarc — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression free survival	time to first progression until the second one	6 months